The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $60.56 in the prior trading day, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $59.5, down -1.75%. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 1.17 million shares were traded. PTCT stock price reached its highest trading level at $60.95 during the session, while it also had its lowest trading level at $58.37.
Ratios:
Our goal is to gain a better understanding of PTCT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.78. For the most recent quarter (mrq), Quick Ratio is recorded 3.57 and its Current Ratio is at 3.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On May 09, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $68.
Citigroup Upgraded its Sell to Neutral on May 07, 2025, while the target price for the stock was maintained at $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 11 ’25 when Reeve Emma sold 15,705 shares for $59.50 per share. The transaction valued at 934,448 led to the insider holds 10,332 shares of the business.
Boulding Mark Elliott sold 24,585 shares of PTCT for $1,508,083 on Sep 12 ’25. The EXEC. VP AND CLO now owns 103,901 shares after completing the transaction at $61.34 per share. On Sep 11 ’25, another insider, Boulding Mark Elliott, who serves as the EXEC. VP AND CLO of the company, sold 22,664 shares for $61.00 each. As a result, the insider received 1,382,504 and left with 103,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 4726566912 and an Enterprise Value of 5210907648. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.68. Its current Enterprise Value per Revenue stands at 2.952 whereas that against EBITDA is 5.823.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.54, which has changed by 0.57992566 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $63.19, while it has fallen to a 52-week low of $34.57. The 50-Day Moving Average of the stock is 14.06%, while the 200-Day Moving Average is calculated to be 20.50%.
Shares Statistics:
The stock has traded on average 1.24M shares per day over the past 3-months and 1409970 shares per day over the last 10 days, according to various share statistics. A total of 79.38M shares are outstanding, with a floating share count of 76.03M. Insiders hold about 4.29% of the company’s shares, while institutions hold 99.99% stake in the company. Shares short for PTCT as of 1756425600 were 6643065 with a Short Ratio of 5.34, compared to 1753920000 on 6016226. Therefore, it implies a Short% of Shares Outstanding of 6643065 and a Short% of Float of 9.609999499999999.
Earnings Estimates
. The current rating of PTC Therapeutics Inc (PTCT) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.05 and low estimates of -$1.38.
Analysts are recommending an EPS of between $8.97 and $6.4 for the fiscal current year, implying an average EPS of $7.93. EPS for the following year is -$2.29, with 7.0 analysts recommending between -$0.35 and -$3.3.
Revenue Estimates
12 analysts predict $187.58M in revenue for. The current quarter. It ranges from a high estimate of $314.85M to a low estimate of $140.3M. As of. The current estimate, PTC Therapeutics Inc’s year-ago sales were $196.79MFor the next quarter, 12 analysts are estimating revenue of $203.43M. There is a high estimate of $276.55M for the next quarter, whereas the lowest estimate is $147.93M.
A total of 16 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.85B, while the lowest revenue estimate was $1.65B, resulting in an average revenue estimate of $1.74B. In the same quarter a year ago, actual revenue was $806.78MBased on 16 analysts’ estimates, the company’s revenue will be $857.37M in the next fiscal year. The high estimate is $1.06B and the low estimate is $531.9M.
